Wood Slams This 3.5/10 European Portfolio as a Tech-Free Museum

When I opened this portfolio, the title alone—"Old World Quality Compounders"—told me everything I needed to know about the philosophy driving these allocations. I have to be completely honest with you: this portfolio looks like a museum exhibit of the 20th century. You are investing in the rearview mirror while the most profound technological convergence in human history is happening right in front of your windshield.

At ARK, we focus entirely on the future, modeling out five-year horizons based on exponential growth curves. You are applying linear thinking to an exponential world. You are betting on legacy consumer habits, traditional branding, and incremental improvements, completely missing the fact that artificial intelligence, robotics, multiomics, energy storage, and blockchain are converging to rewrite the global economy. The next trillion-dollar companies are not selling chocolate bars and leather bags; they are sequencing DNA, scaling autonomous mobility, and writing software that writes itself. You are playing it safe in a world where playing it safe is the most dangerous risk of all.

Let’s look at how you've positioned your capital. A staggering 92.2% of your geographic exposure is locked into Europe. Europe is home to wonderful history, but right now, it is regulating innovation while the US and Asia are incubating it. By anchoring yourself to the European market, you are systematically starving your portfolio of exposure to the software and AI revolution.

You have 19.1% of your wealth in Consumer Staples—companies like Nestle, L'Oreal, and Unilever. These are mature businesses that have run out of innovative ways to deploy capital, relying on incremental price hikes rather than Wright's Law cost declines to drive growth. You also have 7.8% sitting in cash reserves. In an era where AI platforms are expanding their total addressable market by trillions of dollars, holding nearly 8% in idle cash is holding dead capital. Every day that cash sits on the sidelines is a day you are betting against exponential growth curves.

The one saving grace here is ASML at 10.8%. ASML is an absolute cornerstone of the semiconductor ecosystem and a critical enabler of the AI revolution. I applaud this position. But pairing it with LVMH, Hermes, and Ferrari? You are treating the future of technology as just another sector alongside luxury purses and combustion-engine sports cars, completely ignoring the compounding convergence of these innovation platforms.

🚩 Reliance on Backward-Looking Moats: Over 70% of your portfolio relies on "Intangible Assets" like patents and brand heritage. In an age of exponential disruption, brand loyalty does not protect you from a competitor whose AI-driven cost curve is 50% lower than yours. Heritage is not a moat against innovation.

🚩 Missing the Multiomic Revolution: You have 23.5% in Healthcare, anchored by Novo Nordisk, Roche, and AstraZeneca. Novo's work in GLP-1s is commendable, but where is your exposure to CRISPR gene editing, long-read sequencing, or AI-driven drug discovery? You are holding legacy pharma while the entire industry shifts from treating symptoms to curing disease at the DNA level.

🚩 No Exposure to Disruptive Tech Platforms: Aside from ASML's picks-and-shovels, you have zero exposure to the real software innovators. SAP is legacy enterprise software. Where are the neural networks? Where are the autonomous robotics? Where is energy storage? Missing the five major innovation platforms is not conservative; it is reckless.

🚩 Value Traps in Finance and Industrials: Holding Allianz and Siemens means you are exposed to legacy finance and traditional industrials right as digital wallets, decentralized finance (DeFi), and autonomous 3D printing are poised to gut their core business models.

I have to give this portfolio a 3.5 / 10. The score is saved only by your concentrated conviction in ASML and Novo Nordisk, which show you are capable of identifying dominant players. But the overarching strategy is hopelessly tethered to the old world.

To fix this and capture the 10x returns of the next decade, you need to take action:

1. Redeploy your dead capital: Put that 7.8% cash to work in high-conviction, pure-play innovators that are leading the AI and robotics convergence.

2. Trim the "Old World" fat: Liquidate your heavy consumer staples positions (Nestle, Unilever). Selling soap and coffee will not keep pace with the productivity explosion we are about to witness.

3. Broaden your geographic horizons: You must break out of the European regulatory bubble. The most aggressive S-curves in genomics, autonomous mobility, and artificial intelligence are currently scaling in North America and parts of Asia.

4. Invest in Multiomics: Diversify your healthcare allocation away from purely legacy pharmaceuticals and into the genomic revolution.

Remember: The biggest risk is not being invested in innovation during the most transformative period in history. Stop clinging to the past, and start investing in the future.